Abstract:
Highlighting the concerns that muscle loss caused by GLP-1 receptor agonists may accelerate the development of frailty in at-risk older sarcopenic obese patients with potential for physical function limitations, may be responsible for weight loss plateau where GLP-1 seem to stop working, and may trigger the overeating with rebound fat and weight regain upon stopping GLP-1 RA.
Presenting the 5 clinical studies of enobosarm in older patients and in patients with a cancer induced loss of appetite hypocaloric-like state that provide strong scientific rationale for ongoing Phase 2b enobosarm + GLP-1 RA clinical study.
Supporting evidence that enobosarm in combination with a GLP-1 RA may potentially augment the fat reduction with higher quality total weight loss while preserving muscle and physical function
Audience take away:
- Understand the current unmet needs with muscle loss caused by GLP-1 receptor agonists for weight-loss.
- Appreciate the importance of high-quality weight-loss, preferentially removing fat while preserving muscle.
- Learn about the development of new approaches to achieve high-quality weight-loss.
Biography:
Mitchell S. Steiner, M.D., F.A.C.S. has served as Executive Chairman, President and Chief Executive Officer of the Company and as a director of the Company since October 2016. Dr. Steiner was the co-founder of Aspen Park Pharmaceuticals and served as Aspen Park’s Chief Executive Officer, President and Vice Chairman of the Board from July 2014 to October 2016. From 2014 to 2016, Dr. Steiner was a strategic consultant and then the President, Urology and member of senior management of OPKO Health, Inc. (NASDAQ:OPK) and had responsibilities for the launch, marketing, sales and reimbursement of 4Kscore prostate cancer test to urologists and primary care physicians. Dr. Steiner was also the co-founder of GTx, Inc., a men’s health and oncology public company, where he served as Chief Executive Officer and Vice Chairman of Board of Directors from 1997 to 2014. Dr. Steiner is a Board-Certified Urologist and a Fellow of the American College of Surgeons and has held numerous academic appointments, including Assistant Professor of Urology, Cell Biology, and Pathology at Vanderbilt School of Medicine from 1993 to 1995 and Chairman and Professor of Urology, Director of Urologic Oncology and Research and the Chair of Excellence in Urologic Oncology at the University of Tennessee from 1995 to 2004. Dr. Steiner holds a B.A. in Molecular Biology and Chemistry from Vanderbilt University and an M.D. from the University of Tennessee. He performed his surgical and urologic training at The Johns Hopkins Hospital and postdoctoral research fellow in cell biology at Vanderbilt School of Medicine.
